Tetanus Vaccine Market (Updated Version Available)

Report Overview

Tetanus vaccine, also known as tetanus toxoid (TT), is an inactive vaccine used to prevent tetanus. During childhood five doses are recommended, with a sixth given during adolescence. Additional doses every 10 years are recommended. After three doses almost everyone is initially immune. In those who are not up to date on their tetanus immunization a booster should be given within 48 hours of an injury. In those with high risk injuries who are not fully immunized tetanus antitoxin may also be recommended. Making sure women who are pregnant are up to date on their tetanus immunization and, if not, immunizing them can prevent neonatal tetanus.

The vaccine is very safe including during pregnancy and in those with HIV/AIDS. Redness and pain at the site of injection occur in between 25% and 85% of people. Fever, feeling tired, and minor muscles pains occur in less than 10% of people. Severe allergic reactions occur in less than one in 100,000 people.

A number of vaccine combinations include the tetanus vaccine such as DTaP and Tdap which contain diphtheria, tetanus, and pertussis vaccine, and DT and Td which contain diphtheria and tetanus vaccine. DTaP and DT are given to children less than seven years old while Tdap and Td are given to those seven years old and older. The lowercase d and p denote lower strengths of diphtheria and pertussis vaccines.

The tetanus vaccine was developed in 1924 and became available in the United States in the 1940s. Its use resulted in a 95% decrease in the rate of tetanus. It is on the World Health Organizations List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between 0.17 and 0.65 USD per dose as of 2014.In the United States a course of tetanus vaccine is between 25 and 50 USD.

This research report gives detailed data about the major factors influencing the growth of the Tetanus Vaccine market at the national and local level forecast of the market size, in terms of value, market share by region, and segment; regional market positions; segment and country opportunities for growth; Key company profiles, SWOT, product portfolio and growth strategies. It studies the market\'s essential sides such as top participants, expansion strategies, business models, and other market features to improve market insight.

The report forecast global Tetanus Vaccine market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2021-2027.

COVID-19 Impact
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Tetanus Vaccine market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.


First, this report covers the present status and the future prospects of the global Tetanus Vaccine market for 2015-2027.
Market Segmentation
The Tetanus Vaccine market is segmented on the basis of type, application, end-use industry, and region & country.
Key Companies
GlaxoSmithKline plc
Pfizer,Inc
Merck & Co.,Inc
Sanofi Pasteur SA
Biological E
Dano Vaccine &Biological Pvt.Ltd.,
Panera
Shantha Biotechnics Ltd
At the same time, we classify Tetanus Vaccine according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.

Market by Order Type
Diphtheria and tetanus (DT) vaccines
Diphtheria, tetanus, and pertussis (whooping cough) (DTaP) vaccines
Tetanus and diphtheria (Td) vaccines
Tetanus, diphtheria, and pertussis (Tdap) vaccines
Market by Application
Adult
Pediatric

Market Segment as follows:
By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]

The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Tetanus Vaccine market for the forecast period 2021 - 2027?
• What are the driving forces in the Tetanus Vaccine market for the forecast period 2021 - 2027?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Tetanus Vaccine industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?

For any other requirements, please feel free to contact us and we will provide you customized report.